PD-1 blockade after bispecific LV20.19 CAR-T modulates CAR T-cell immunophenotype without meaningful clinical response
نویسندگان
چکیده
منابع مشابه
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
Antibodiesblocking theprogrammeddeath1 receptor (PD-1) onTcells produce tumor regression in multiple cancers by disrupting the PD-L1/ PD-1 (programmed death-ligand 1/programmed cell death protein 1) immune inhibitory axis. This approach to cancer immunotherapy would seem to be an ideal partner for chimeric antigen receptor (CAR)– modified T-cell therapies but is, as yet, untested in this settin...
متن کاملBlockade of PD-1 immunosuppression boosts CAR T-cell therapy
The presence of an immunosuppressive microenvironment can limit the full potential of adoptive T cell immunotherapy. However, specific blockade of the PD-1 immunosuppressive pathway can significantly enhance the function of gene-modified T cells expressing a chimeric antigen receptor (CAR) leading to enhanced tumor eradication.
متن کاملHuman CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
Following immune attack, solid tumors upregulate coinhibitory ligands that bind to inhibitory receptors on T cells. This adaptive resistance compromises the efficacy of chimeric antigen receptor (CAR) T cell therapies, which redirect T cells to solid tumors. Here, we investigated whether programmed death-1-mediated (PD-1-mediated) T cell exhaustion affects mesothelin-targeted CAR T cells and ex...
متن کاملCAR T- cellها: درمانی هدف‌مند در سرطان
سابقه و هدف: با توسعه و پیشرفت روزافزون در زمینة ایمنی‌درمانی تومورها، امروزه توجه خاصی به درمان‌های ایمنی انواع سرطان‌ها معطوف شده است. درمان‌های بر پایة گیرنده‌های کایمری آنتی‌ژن‌ها (CARs)، یکی از انواع درمان‌های مبتنی بر سلول‌های Tی تغییریافته به‌شمار می‌رود که به‌صورت هدف‌مند تنها روی سلول‌های توموری فرد و نه سلول‌های طبیعی اثر می‌گذارد. مواد و روش‌ها: پژوهش‌ها در دهه‌های اخیر حاکی از این ا...
متن کاملClinical Pharmacological Considerations on CAR-T Cell Therapy for Cancer
During the past 70 years, cancer therapy has undergone extensive growth from pharmacotherapy toward targeted therapy, poised upon the considerations of efficacy and safety of clinically applied drugs [1]. The strategy behind this growth was to optimize the structures of the drugs, from synthesized chemical entities to biologics, to enhance the specificity between drugs and disease targets for b...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Haematologica
سال: 2021
ISSN: 1592-8721,0390-6078
DOI: 10.3324/haematol.2021.278461